WMS 2023 poster: Updated demographics and safety data from patients with nonsense mutation Duchenne muscular dystrophy receiving ataluren in the STRIDE Registry
This poster, presented at WMS 2023, explores the safety data and demographics of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) after receiving ataluren
Explore the patient demographics for patients in the STRIDE Registry
Compare treatment-related adverse events in patients receiving ataluren with and without accompanying corticosteroid use
Understand the safety data of ataluren through this long-term, real-world analysis
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300184 | January 2024
Sign in or register to access exclusive content on this site